AstraZeneca PLC
New York Stock ExchangeTotal Valuation
AstraZeneca PLC carries a market capitalization of 252.33B, placing it among publicly traded companies globally. Its enterprise value stands at 321.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 252.33B |
| Enterprise Value | 321.42B |
Share Statistics
AstraZeneca PLC currently has 1.55B shares outstanding.
| Shares Outstanding | 1.55B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
AstraZeneca PLC trades at a trailing price-to-earnings ratio of 28.14. The price-to-sales ratio is 4.79, and the price-to-book ratio stands at 5.85.
| PE Ratio | 28.14 |
| PS Ratio | 4.79 |
| PB Ratio | 5.85 |
| P/TBV Ratio | -34.16 |
| P/FCF Ratio | 13.86 |
| P/OCF Ratio | 21.46 |
Enterprise Valuation
On an enterprise value basis, AstraZeneca PLC trades at an EV/EBITDA multiple of 23.01 and an EV/FCF ratio of 14.09. The EV/Sales ratio of 5.24 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 23.01 provides insight into valuation relative to core operating earnings.
| EV / Sales | 5.24 |
| EV / EBITDA | 23.01 |
| EV / EBIT | 23.01 |
| EV / FCF | 14.09 |
Financial Position
AstraZeneca PLC maintains a current ratio of 0.89, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 64.00, indicating elevated leverage, while an interest coverage ratio of 8.00 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 0.89 |
| Quick Ratio | 0.16 |
| Debt / Equity | 64.00 |
| Debt / EBITDA | 2.31 |
| Interest Coverage | 8.00 |
Financial Efficiency
AstraZeneca PLC posts a return on equity of 21.99 and a return on invested capital of 14.22.
| Return on Equity (ROE) | 21.99 |
| Return on Assets (ROA) | 9.15 |
| Return on Invested Capital (ROIC) | 14.22 |
| Return on Capital Employed (ROCE) | 14.84 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.66 |
Taxes
Over the trailing twelve months, AstraZeneca PLC has paid 2.13B in income taxes, reflecting an effective tax rate of 16.95.
| Income Tax | 2.13B |
| Effective Tax Rate | 16.95 |
Stock Price Statistics
AstraZeneca PLC's stock has declined approximately -1.09422% over the past 52 weeks. The 50-day moving average sits at 169.10, while the 200-day moving average is 183.89.
| Beta (5Y) | N/A |
| 52-Week Price Change | -1.09422% |
| 50-Day Moving Average | 169.10 |
| 200-Day Moving Average | 183.89 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, AstraZeneca PLC generated 61.37B in revenue and converted that into 10.45B in net income, yielding earnings per share of 6.69. EBITDA reached 13.97B, while operating income came in at 13.97B.
| Revenue | 61.37B |
| Gross Profit | 50.25B |
| Operating Income | 13.97B |
| Pretax Income | 12.59B |
| Net Income | 10.45B |
| EBITDA | 13.97B |
| EBIT | 13.97B |
| Earnings Per Share (EPS) | 6.69 |
Balance Sheet
AstraZeneca PLC holds 4.97B in cash and equivalents against 32.24B in total debt, resulting in a net debt position of 24.60B. Total book value stands at 50.30B, with working capital of -3.59B providing operational flexibility.
| Cash & Cash Equivalents | 4.97B |
| Total Debt | 32.24B |
| Net Debt | 24.60B |
| Equity (Book Value) | 50.30B |
| Book Value Per Share | 32.43 |
| Working Capital | -3.59B |
Cash Flow
AstraZeneca PLC produced 13.70B in operating cash flow over the past twelve months. After subtracting -7.66B in capital expenditures, free cash flow totaled 6.04B - equivalent to 3.90 per share.
| Operating Cash Flow | 13.70B |
| Capital Expenditures | -7.66B |
| Free Cash Flow | 6.04B |
| FCF Per Share | 3.90 |
Margins
AstraZeneca PLC operates with a gross margin of 81.88, reflecting its pricing power and cost economics. The operating margin of 22.77 and net profit margin of 17.02 provide insight into operational efficiency.
| Gross Margin | 81.88 |
| Operating Margin | 22.77 |
| Pretax Margin | 20.51 |
| Profit Margin | 17.02 |
| EBITDA Margin | 22.77 |
Dividends & Yields
The company's payout ratio of 46.86 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 3.16 |
| Dividend Yield | N/A |
| Payout Ratio | 46.86 |
| Shareholder Yield | 2.61 |
| FCF Yield | 7.21 |
Stock Splits
AstraZeneca PLC's most recent stock split took place on February 2, 2026 with a 2:1 split ratio.
| Last Split Date | 2/2/2026 |
| Split Ratio | 2:1 |
Scores
AstraZeneca PLC posts an Altman Z-Score of 4.82, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.82 |